

These results provide confirmation of the clinical relevance of Oralair.
Obtention of the European approval in both adults and children through a Mutual Recognition Procedure.
First results of a new phase IIb/III clinical trial (VO59.08) conducted in allergic rhinitis caused by birch pollen.
The tablet for allergic rhinitis caused by exposure to dust mites has been given the following brand name: “ACTAIR”
Net profit up 11%, Strong research and investment effort, Positive net financial position, Annual growth guidance maintained at 10%
2nd quarter growth remained high at 9% (organic 8%), but slowed down compared with the very strong start of the year. Sales growth over the first half-year remained strong at 12% (organic 11%).
Release of the first year outcome of the VO 57.07 clinical study on a sublingual house dust mite desensitization tablet.
Strong growth in results, Sales up 16%, Net profit up 17%
Sound financial position
Proposed increase in dividend
Signing of an exclusive partnership agreement for the promotion and distribution of Stallergenes diagnostic and treatment products
The development of Stallergenes tablet-form pharmaceutical products will now be coordinated within a program dubbed “STALAIR®”.
Pediatric extension of the indications for Stallergenes sublingual tablets for desensitization to grass pollens.